[EN] MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOBENZAZÉPINE À SUPPORT MACROMOLÉCULAIRE
申请人:BOLT BIOTHERAPEUTICS INC
公开号:WO2020252254A1
公开(公告)日:2020-12-17
The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.
Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders
申请人:Scott Ian Leslie
公开号:US20090170841A1
公开(公告)日:2009-07-02
The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
Reaction products of the reaction between reactants comprised of the following:
A) at least one compound of formula I below
RX(EO)
n
(PO)
m
(BO)
p
H (I)
wherein R is a substituted or unsubstituted, saturated or unsaturated, organic group having from 4 to 36 carbon atoms; X is —O—, —S—, or —NR
2
— where R
2
is hydrogen or a C
1
-C
8
alkyl group; n is a number from 0 to 100; m is a number from 0 to 50; and p is a number from 0 to 50; provided that the sum of n, m, and p is at least 1; and
B) a polyaldehyde of formula II below
1
where R
1
is a C
1
-C
30
straight or branched chain optionally substituted alkyl or alkenyl group, an optionally substituted aromatic group, or an optionally substituted cycloalkyl or cycloalkenyl group; x is 0 or 1; and h is a number of at least two.
由以下物质组成的反应物之间的反应产物:
A) 至少一种下式 I 的化合物
RX(EO)
n
(PO)
m
(BO)
p
H (I)
其中 R 是具有 4 至 36 个碳原子的取代或未取代、饱和或不饱和有机基团;X 是 -O-、-S- 或 -NR
2
- 其中 R
2
是氢或 C
1
-C
8
烷基;n 是 0 至 100 的数字;m 是 0 至 50 的数字;p 是 0 至 50 的数字;条件是 n、m 和 p 之和至少为 1;以及
B) 下式 II 的聚醛
1
其中 R
1
是 C
1
-C
30
直链或支链任选取代的烷基或烯基、任选取代的芳基或任选取代的环烷基或环 烯基;x 为 0 或 1;h 至少为 2。
[EN] POLYALDEHYDE REACTION PRODUCTS<br/>[FR] PRODUITS DE REACTION DE POLYALDEHYDE
申请人:COGNIS CORP
公开号:WO2002050146A1
公开(公告)日:2002-06-27
Reaction products of the reaction between reactants comprised of the following: A) at least one compound of formula (1) below wherein R is a substituted or unsubstituted, saturated or unsaturated, organic group having from 4 to 36 carbon atoms; X is-0-, -S-, or NR2- where R2 is hydrogen or a C1-C8 alkyl group; n is a number from 0 to 100; m is a number from 0 to 50; and p is a number from 0 to 50; provided that the sum of n, m, and p is at least 1; and B) a polyaldehyde of formula (II) below where R1 is a C1-C30 straight or branched chain optionally substituted alkyl or alkenyl group, and optionally substituted aromatic group, or an optionally substituted cycloalkyl or cycloalkenyl group; x is 0 or 1; and h is a number of at least two.
[EN] AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF<br/>[FR] COMPOSÉS D'AMINOBENZAZÉPINE, IMMUNOCONJUGUÉS ET LEURS UTILISATIONS
申请人:BOLT BIOTHERAPEUTICS INC
公开号:WO2020252294A1
公开(公告)日:2020-12-17
The application relates to immunoconjugates of Formula (I) comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula (II) comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The application further provides the above- mentioned immunoconjugates for use in methods of treating cancer.